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Abstract We report here oxidation of propylbenzene and 3-
chlorostyrene by wild-type cytochrome P450 BM-3 with high
turnover (479 nmol 1-phenyl-1-propanol/min/nmol P450 and 300
nmol 3-chlorostyrene oxide/min/nmol P450). Furthermore, the
residue size at position 87 of P450 BM-3 was found to play
critical roles in determining stereoselectivity in oxidation of
propylbenzene and 3-chlorostyrene. Replacement of Phe87 with
Val, Ala and Gly resulted in decreases in optical purity of
produced (R)-(+)-1-phenyl-1-propanol from 90.0 to 37.4, 26.0
and 315.6% e.e., respectively, and in increases in those of
produced (R)-(+)-3-chlorostyrene oxide from 361.0 to 338.0,
67.0 and 94.6% e.e., respectively. ß 2001 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
Cytochrome P450 (P450) BM-3 from Bacillus megaterium,
which catalyzes the hydroxylation and epoxidation of long-
chain saturated and unsaturated fatty acids, respectively, is
one of the best-characterized P450 enzymes [1,2]. This soluble
bacterial P450 is a catalytically self-su⁄cient P450, which is a
single polypeptide naturally consisting of a P450 and a di£a-
vin NADPH-P450 reductase. It is highly active with catalytic
turnover of several thousands per minute for fatty acid oxi-
dation, and catalyzes the oxidation of fatty acids with high
stereoselectivity [3^5]. For instance, 98% of 15- and 14-hy-
droxypalmitic acids produced through palmitic acid hydroxy-
lation by P450 BM-3 are in the R con¢guration [5]. P450 BM-
3 oxidizes eicosapentaenoic acid stereoselectively to
17(S),18(R)-epoxyeicosatetraenoic acid with an optical purity
of 94% e.e. [4].
Here, we demonstrated for the ¢rst time that P450 BM-3
shows high activities towards propylbenzene and 3-chlorostyr-
ene with considerable stereoselectivity. Furthermore, reaction
analysis using its mutants revealed that the stereoselectivity is
under the control of the size of the residue at position 87 of
this enzyme. Phe87 is one of the most studied residues in P450
BM-3 with respect to its activity and selectivity [3,10,11]. The
replacement of Phe87 by other amino acids, such as Ala, Gly,
Tyr and Val, a¡ected the activity and regio- and/or stereo-
selectivity toward its original substrates, long-chain fatty acids
such as laurate [10,11], myristate [10] and arachidonic acid [3].
Our ¢ndings as to arti¢cial substrates, propylbenzene and 3-
chlorostyrene, provide new clues for understanding the ways
in which P450 BM-3 recognizes substrate structures and
Phe87 of the P450 controls spatial coordination of these sub-
strates in the active site. These results indicate the high po-
tential of P450 BM-3 and its mutants for the preparation of
useful chiral compounds.
2. Materials and methods
2.1. Chemicals
(R)-(+)-1-Phenyl-1-propanol, (S)-(3)-1-phenyl-1-propanol and (R)-
(+)-3-chlorostyrene oxide were purchased from Aldrich (Milwaukee,
WI, USA). 1-Phenyl-2-propanol and 3-phenyl-1-propanol were pur-
chased from Tokyo Kasei Kogyo (Tokyo, Japan). All other chemicals
used in this study were of reagent grade.
2.2. Preparation of P450 BM-3 and its mutant enzymes
The P450 BM-3 mutants were obtained by replacement of Phe87
with Val (F87V), Ala (F87A) or Gly (F87G) as described previously
[6]. The expression and puri¢cation of P450s and determination of the
concentration of P450s were carried out as described previously [6].
2.3. Enzyme activity assay
Throughout the reaction, the concentration of the substrates was
maintained enough higher than their Kd values (Tables 2 and 3) to get
a maximum reaction rate. To measure the NADPH consumption rate,
60 Wl of a 1.5 WM P450 sample was mixed with 480 Wl of 0.1 M Tris^
HCl bu¡er (pH 7.4) containing 6 Wl of 1 M propylbenzene or
3-chlorostyrene in dimethyl sulfoxide (DMSO). The mixture was al-
lowed to stand for 2 min at 25‡C, then 60 Wl of 3.5 mM NADPH was
added to start the reaction. The ¢nal volume of the reaction mixture
was 600 Wl and concentrations of the components at the beginning of
the reaction were as follows: P450 (0.15 WM), Tris^HCl (80 mM),
substrate (10 mM), and NADPH (0.35 mM). NADPH consumption
was monitored at 340 nm with a Shimadzu MultiSpec-1500 spectro-
photometer (Kyoto, Japan) at 25‡C for 20 s. The NADPH concen-
tration was calculated using OM = 6200 M31 cm31 [7].
The substrate oxidation activity was calculated by multiplying the
NADPH consumption rate by the coupling e⁄ciency. To measure the
coupling e⁄ciency, 100 Wl of a 25 WM P450 sample was mixed with
4800 Wl of 0.1 M Tris^HCl bu¡er (pH 7.4) containing 80 U of catalase
and 50 Wl of 1 M propylbenzene or 3-chlorostyrene in DMSO. After
standing for 2 min, 100 Wl of 20.0 mM NADPH was added, and the
reaction mixture was incubated for 20 min at 25‡C to allow all
NADPH to be consumed. The ¢nal volume of the reaction mixture
was 5000 Wl and concentrations of the components at the beginning of
the reaction were as follows: P450 (0.5 WM), Tris^HCl (96 mM),
catalase (160 U/ml), substrate (10 mM), and NADPH (0.4 mM).
Control experiments were carried out as described above except for
the absence of NADPH. After incubation, 50 Wl of 200 mM 4-phenyl-
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1-butanol in DMSO was added to the reaction mixtures as an in-
ternal standard, and the reaction mixtures were extracted twice
with chloroform (6 ml in total). The extracts were evaporated to
about 100 Wl and then used for gas^liquid chromatography (GC)
and GC-mass spectrometry (MS) analyses. The amount of product
was calculated with a standard calibration curve obtained using au-
thentic samples.
2.4. GC and GC-MS analyses
GC analysis was performed with a Shimadzu GC-17A gas chroma-
tograph equipped with a £ame ionization detector and a split injection
system, and ¢tted with a capillary column DB-17 (30 mU0.554 mm
i.d. ; JpW Scienti¢c, Folsom, CA, USA). The column temperature
was initially 100‡C, and was then raised to 280‡C at a rate of 5‡C/
min and maintained at that temperature for 20 min. The injector and
detector were operated at 280‡C. Helium was used as the carrier gas
at 30 kPa/cm2.
GC-MS analysis was performed on a GC-MS QP5050 (Shimadzu)
with a GC-17A gas chromatograph equipped with a capillary column
(HR-1, 25 mU0.25 mm i.d.; Shinwa Kako, Kyoto, Japan) at 150‡C.
Helium was used as the carrier gas at 225 kPa/cm2. MS was per-
formed in the electron impact mode at 70 eV with a source temper-
ature of 250‡C. Split injection was employed with the injection port at
250‡C.
Table 1
Product distribution of propylbenzene hydroxylated by P450 BM-3 and its mutantsa
Products ratio (%)
WT F87V F87A F87G
1-Phenyl-1-propanol 99.2 þ 0.4 80.0 þ 1.1 34.5 þ 1.4 67.8 þ 1.8
1-Phenyl-2-propanol 0.8 þ 0.4 19.0 þ 0.8 54.0 þ 1.4 25.9 þ 1.2
3-Phenyl-1-propanol 0 1.0 þ 0.6 11.5 þ 1.1 6.3 þ 1.1
aAll results are given as means þ S.D. for three individual experiments.
Fig. 1. Absorbance spectral changes on propylbenzene (A) and 3-chlorostyrene (B) binding to P450 BM-3. P450 BM-3 (3.8 WM) in Tris^HCl
bu¡er (100 mM, pH 7.4) was titrated with a freshly prepared solution of propylbenzene or 3-chlorostyrene and the absorbance changes were re-
corded following each addition: for propylbenzene, ¢nal concentrations of 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.1, 0.14, 0.18, 0.22, 0.26 and 0.32
mM; for 3-chlorostyrene, ¢nal concentrations of 0.08, 0.1, 0.12, 0.14, 0.16, 0.18, 0.2, 0.24, 0.28, 0.32, 0.42 and 0.52 mM. A plot of 1/[ESi] ver-
sus 1/[Si] for each substrate (C), where [ESi] was calculated from the change in the absorbance (vAi) using the equation [ESi] =vAiU[P450]/
vAmaxUvAi was determined by subtracting the absorbance at 422 nm (trough) from that at 388 nm (peak) and vAmax as the maximum vAi
obtained from palmitic acid binding to P450 BM-3; [Si] = [Stotal]3[ESi].
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2.5. Resolution of 1-phenyl-1-propanol and 3-chlorostyrene oxide
enantiomers
The propylbenzene reaction sample was extracted twice with
chloroform (6 ml in total), evaporated to dryness, and then dissolved
in 5% (v/v) of 2-propanol in n-hexane for HPLC analysis. HPLC
analysis was carried out on a Chiralcel OJ column (4.6 mm
i.d.U250 mm; Daicel Chemical Industries, Osaka, Japan), at a £ow
rate of 0.5 ml/min with n-hexane/2-propanol (95:5, by volume) as the
eluent. The eluent was monitored at 254 nm.
The enantiomers of 3-chlorostyrene oxide were analyzed by GC-MS
essentially under the same conditions as described above on a Cyclo-
dex-B chirality-sensitive GC column (30 mU0.25 mm i.d.; Chrom-
pack, Middelburg, The Netherlands) using a 100‡C isotherm.
2.6. Spectral binding studies
The substrate-induced spectral shifts of P450 BM-3 enzymes were
recorded with a Shimadzu MultiSpec-1500 spectrophotometer at
25‡C. Propylbenzene and 3-chlorostyrene dissolved in DMSO at con-
centrations of 20 mM were freshly prepared for the analysis. For each
substrate, the substrate solution was added to the enzyme solution
(600 Wl) containing 3.8 WM P450 in 0.1 M Tris^HCl (pH 7.4) in a
cuvette, and the same volume of DMSO was added to the reference
cuvette containing the enzyme solution. For each substrate for all
enzymes, triplicate binding assays with 12 variations of substrate con-
centration were performed. The change in absorbance (vA) was de-
termined by subtracting the absorbance at 422 nm (trough) from that
at 388 nm (peak). The maximum heme spin-state shift of wild-type
binding to palmitic acid was taken as 100% heme spin-state shift.
Data analysis and calculations were carried out according to the
methods described elsewhere [7].
3. Results
3.1. Hydroxylation of propylbenzene
Wild-type P450 BM-3 hydroxylated propylbenzene mainly
to 1-phenyl-1-propanol (99.2% of the total product) with co-
production of a small amount of 1-phenyl-2-propanol (0.8%
of the total product). These products were identi¢ed on the
basis of co-elution with authentic samples on GC (retention
time for 1-phenyl-1-propanol 12.8 min, for 1-phenyl-2-propa-
nol 12.3 min) and also the results of GC-MS. P450 BM-3
mutants F87V, F87A and F87G all hydroxylated propylben-
zene to a mixture of 1-phenyl-1-propanol, 1-phenyl-2-propa-
nol and 3-phenyl-1-propanol (identi¢ed on the basis of the co-
elution with the authentic sample on GC and the results of
GC-MS, retention time on GC 16.0 min). The product distri-
bution was signi¢cantly in£uenced by the size of the residue at
position 87 (Table 1).
The resolution of the two enantiomers of 1-phenyl-1-prop-
anol was carried out on a Chiralcel OJ HPLC column. The
retention times for (R)-(+)-1-phenyl-1-propanol and (S)-(3)-
1-phenyl-1-propanol were 20.1 and 19.1 min, respectively.
Wild-type produced (R)-(+)-1-phenyl-1-propanol with 90%
e.e., but the optical purity of the produced (R)-(+)-1-phenyl-
1-propanol was decreased to 37.4, 26.0 or 315.6% e.e. by
replacement of Phe87 with Val, Ala or Gly, respectively (Ta-
ble 2). These observations indicated that the size of the residue
at position 87 of P450 BM-3 determined the proportion of the
two enantiomers.
The activity of P450 BM-3 towards propylbenzene did not
change signi¢cantly with the replacement of Phe87 by these
small residues, but the coupling e⁄ciency decreased by 30^
40% (Table 2).
Substrate binding to P450 usually triggers a heme spin-state
shift from low to high, and it can be monitored as changes in
P450 absorbance spectra. Propylbenzene binds to wild-type
with a maximum heme spin-state shift of 35.0% and a disso-
ciation constant of 73.5 WM (Fig. 1 and Table 2). The max-
imum heme spin-state shift of P450 BM-3 triggered by the
binding of propylbenzene was increased by replacement of
Phe87 with small amino acid residues (Table 2). The replace-
ment of Phe87 with small amino acid residues also increased
the a⁄nity of P450 BM-3 towards propylbenzene, re£ected in
a reduction of the dissociation constants (Table 2).
3.2. Epoxidation of 3-chlorostyrene
The wild-type and its mutants, F87V, F87A and F87G,
catalyzed the epoxidation of 3-chlorostyrene to 3-chlorostyr-
ene oxide, which was identi¢ed on the basis of the co-elution
with authentic sample on GC-MS and also the results of MS.
No other products were detected.
The 3-chlorostyrene oxide produced was resolved into two
peaks with retention times of 26.6 and 27.8 min on the chir-
ality-sensitive GC column. The peak with the retention time
of 26.6 min was identi¢ed as (R)-(+)-3-chlorostyrene oxide on
Table 2
Binding and oxidation of propylbenzene by P450 BM-3 and its mutantsa
WT F87V F87A F87G
Optical purity of produced (R)-(+)-1-phenyl-1-propanol (% e.e.)b 90.0 37.4 26.0 315.6
Activity (nmol phenylpropanol/min/nmol P450) 479 þ 29 546 þ 34 439 þ 21 661 þ 37
Coupling e⁄ciency (%) 60.0 þ 4.7 38.0 þ 4.2 35.5 þ 3.8 44.7 þ 5.1
High-spin heme (%) 35.0 þ 5.1 81.1 þ 6.2 41.4 þ 3.9 48.2 þ 4.3
Dissociation constant (Kd, WM) 73.5 þ 5.4 44.9 þ 4.7 34.7 þ 4.2 20.1 þ 2.6
aAll results are given as means þ S.D. for three individual experiments.
bS.D. was within 0.8%.
Table 3
Oxidation and binding of 3-chlorostyrene by P450 BM-3 and its mutantsa
WT F87V F87A F87G
Optical purity of produced (R)-(+)-chlorostyrene oxide (% e.e.)b 361.0 338.0 67.0 94.6
Activity (nmol 3-chlorostyrene oxide/min/nmol P450) 300 þ 33 769 þ 38 196 þ 24 900 þ 41
Coupling e⁄ciency (%) 46.6 þ 5.2 52.6 þ 4.9 47.9 þ 5.1 52.3 þ 5.7
High-spin heme (%) 29.5 þ 4.8 56.6 þ 4.9 54.3 þ 4.2 54.1 þ 5.6
Dissociation constant (Kd, WM) 107 þ 10 90.8 þ 6.1 72.7 þ 5.5 66.3 þ 4.5
aAll results are given as means þ S.D. for three individual experiments.
bS.D. was within 0.6%.
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the basis of co-elution with an authentic sample on the chir-
ality-sensitive GC column and also the results of MS. The
peak with the retention time of 27.8 min was identi¢ed as
(S)-(3)-3-chlorostyrene oxide on the basis of the results of
MS, which indicates that the two peaks resolved on the chir-
ality-sensitive GC column were the same compound. It was of
interest that the optical purity of the produced (R)-(+)-3-
chlorostyrene oxide was increased from 361.0 to 338.0,
67.0 and 94.6% e.e. by replacement of Phe87 with Val, Ala
and Gly, respectively (Table 3). Thus, the size of the residue at
position 87 of P450 BM-3 determines the proportion of the
two enantiomers in 3-chlorostyrene oxidation as well as in
propylbenzene oxidation.
The coupling e⁄ciencies of wild-type and the three mutants
are similar to each other, but the 3-chlorostyrene epoxidation
activity of P450 BM-3 was increased two- or three-fold by
replacement of Phe87 with Val or Gly, respectively (Table
3). However, mutation of F87A decreased the 3-chlorostyrene
epoxidation activity by 35% (Table 3).
3-Chlorostyrene binds to the wild-type with a maximum
heme spin-state shift of 29.5% and a dissociation constant
of 107 WM (Fig. 1 and Table 3). The maximum heme spin-
state shift of P450 BM-3 triggered by binding of 3-chlorostyr-
ene was signi¢cantly increased by replacement of Phe87 with
small amino acid residues (Table 3). The replacement of
Phe87 with small amino acid residues also increased the a⁄n-
ity of P450 BM-3 towards 3-chlorostyrene, re£ected in the
reduction of the dissociation constants (Table 3).
4. Discussion
P450 BM-3 has been crystallized and its structural data are
available. The substrate binding site of P450 BM-3 is a long,
narrow channel [8], which seems suitable for binding of long-
chain fatty acids. However, the results of the present study
indicate that propylbenzene and 3-chlorostyrene with struc-
tures di¡erent from long-chain fatty acids can also e⁄ciently
bind to P450 BM-3, and that P450 BM-3 also shows high
activity towards these two compounds.
Due to the £exibility of long-chain fatty acids in the sub-
strate binding site of P450 BM-3, the enzyme hydroxylates the
substrates at g-1, g-2, g-3 carbons [5,8^10]. Wild-type P450
BM-3 hydroxylates propylbenzene at g-2 carbons (99.2%) in-
dicating that propylbenzene in the binding site of P450 BM-3,
unlike long-chain fatty acids, may lack su⁄cient £exibility
resulting in g-1 or terminal hydroxylation. However, replace-
ment of Phe87 with Ala (F87A) greatly increases the hydroxy-
lation at g-1 and the terminal carbons of propylbenzene. This
indicates that the £exibility of propylbenzene in the binding
site of F87A was signi¢cantly increased due to the removal of
the Phe87 side chain and the increment of the space of the
binding site around the heme iron. Wild-type BM-3 hydroxy-
lated propylbenzene with high stereoselectivity. However, the
stereoselectivity was decreased by replacement of Phe87 with
small amino acid residues. This also may have been because of
increased free space in the binding site due to removal of the
large residue.
The epoxidation of 3-chlorostyrene to 3-chlorostyrene oxide
by P450 BM-3 also showed stereoselectivity. Although the
stereoselectivity of the wild-type is not so strict, the propor-
tion of (R)-(3)-3-chlorostyrene oxide was gradually increased
by replacement of Phe87 with large to small amino acid res-
idues. The production of (S)-(+)-3-chlorostyrene oxide almost
disappeared when Phe87 was replaced with the smallest resi-
due, Gly, and (R)-(+)-3-chlorostyrene oxide of high optical
purity (96.4% e.e.) was obtained with F87G. In this case,
increasing the free space in the substrate binding site created
a superior stereoselective catalyst.
The e¡ects of position 87 in P450 BM-3 on its activities,
regio- and/or stereoselective oxidation of long-chain fatty
acids have been extensively studied [3,10,11]. F87A hydroxy-
lates laurate and myristate on terminal carbon [10], unlike
wild-type on subterminal carbons, and F87V oxidizes arachi-
donic acid and eicosapentaenoic acid with high stereoselectiv-
ity [3]. In this work, we observed that residue size at position
87 of P450 BM-3 also determines its stereoselectivity in pro-
pylbenzene and 3-chlorostyrene oxidation. These interesting
results together with those of previous studies on modi¢cation
of substrate speci¢city by site-directed mutagenesis [12^16]
may be useful for engineering of P450 BM-3 to synthesize
other useful chiral compounds.
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